FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2770798942> ?p ?o ?g. }

• W2770798942 endingPage "e173776" @default.
• W2770798942 startingPage "e173776" @default.
• W2770798942 abstract "Based on evidence of human papillomavirus (HPV)-induced immune evasion, immunotherapy may be an attractive strategy in cervical cancer. Ipilimumab is a fully humanized monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 (CTLA-4), which acts to downregulate the T-cell immune response.To assess the safety and antitumor activity of ipilimumab in recurrent cervical cancer.A multicenter trial was designed for patients with metastatic cervical cancer (squamous cell carcinoma or adenocarcinoma) with measurable disease and progression after at least 1 line of platinum chemotherapy. A run-in safety cohort using ipilimumab, 3 mg/kg, every 21 days for 4 cycles in 6 patients was followed by a phase II cohort of ipilimumab, 10 mg/kg, every 21 days for 4 cycles and then 4 cycles of maintenance therapy every 12 weeks for patients demonstrating radiologic response or stabilization. Immune correlative studies were performed on peripheral blood before and after therapy on archival tissue and fresh tumor obtained prior to registration and 7 days after cycle 2. The study was conducted from December 3, 2012, to September 15, 2014. The data were analyzed from April 2016 to June 2016 and in July 2017.The primary end points were safety and objective response rate. Immune analyses were performed on blood and tumor tissue.A total of 42 women (median age, 49 years; range, 23-78 years) were enrolled (29 [69%] squamous cell cervical cancer and 13 [31%] adenocarcinoma; 37 [93%] of 40 patients with tissue available for analysis had HPV-positive confirmation; there was no archival tissue for 2 women). Grade 3 toxic effects included diarrhea in 4 patients, 3 of whom had colitis. Of 34 patients evaluated for best response (Response Evaluation Criteria in Solid Tumors, version 1.1), 1 patient had partial response and 10 had stable disease. The median progression-free survival and overall survival were 2.5 months (95% CI, 2.1-3.2 months) and 8.5 months (95% CI, 3.6-not reached; 1 patient was still alive), respectively. Intratumoral pretreatment CD3, CD4, CD8, FoxP3, indoleamine 2,3-dioxygenase, and programmed cell death ligand 1 (PD-L1) expression was not predictive of benefit and did not significantly change with treatment. Multicolor flow cytometry on peripheral lymphocytes revealed a treatment-dependent increase of inducible T-cell costimulator, human leukocyte antigen-antigen D related, and PD-1 during initial treatment, which returned to baseline during maintenance.Ipilimumab was tolerable in this population but did not show significant single-agent activity. Immune changes were induced by anti-CTLA-4 therapy but did not correlate with clinical activity. Changes in these markers may guide further treatment strategies." @default.
• W2770798942 created "2017-12-04" @default.
• W2770798942 creator A5000409705 @default.
• W2770798942 creator A5008158683 @default.
• W2770798942 creator A5011136856 @default.
• W2770798942 creator A5011411233 @default.
• W2770798942 creator A5018001559 @default.
• W2770798942 creator A5019722619 @default.
• W2770798942 creator A5026047065 @default.
• W2770798942 creator A5028677586 @default.
• W2770798942 creator A5033865459 @default.
• W2770798942 creator A5038405310 @default.
• W2770798942 creator A5042137756 @default.
• W2770798942 creator A5042345692 @default.
• W2770798942 creator A5042554447 @default.
• W2770798942 creator A5044874564 @default.
• W2770798942 creator A5045663008 @default.
• W2770798942 creator A5046031005 @default.
• W2770798942 creator A5046159625 @default.
• W2770798942 creator A5048048621 @default.
• W2770798942 creator A5049940232 @default.
• W2770798942 creator A5051505642 @default.
• W2770798942 creator A5057738047 @default.
• W2770798942 creator A5078857320 @default.
• W2770798942 creator A5086730784 @default.
• W2770798942 creator A5089503365 @default.
• W2770798942 creator A5090809833 @default.
• W2770798942 date "2018-07-12" @default.
• W2770798942 modified "2023-10-09" @default.
• W2770798942 title "Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma" @default.
• W2770798942 cites W1857980043 @default.
• W2770798942 cites W1985447596 @default.
• W2770798942 cites W2019607817 @default.
• W2770798942 cites W2033221360 @default.
• W2770798942 cites W2066671159 @default.
• W2770798942 cites W2128792706 @default.
• W2770798942 cites W2152980179 @default.
• W2770798942 cites W2155926280 @default.
• W2770798942 cites W2196803223 @default.
• W2770798942 cites W2409067216 @default.
• W2770798942 cites W2560367415 @default.
• W2770798942 cites W2569537049 @default.
• W2770798942 cites W2738732123 @default.
• W2770798942 cites W2740572218 @default.
• W2770798942 cites W4245847758 @default.
• W2770798942 doi "https://doi.org/10.1001/jamaoncol.2017.3776" @default.
• W2770798942 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6145732" @default.
• W2770798942 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29145543" @default.
• W2770798942 hasPublicationYear "2018" @default.
• W2770798942 type Work @default.
• W2770798942 sameAs 2770798942 @default.
• W2770798942 citedByCount "106" @default.
• W2770798942 countsByYear W27707989422018 @default.
• W2770798942 countsByYear W27707989422019 @default.
• W2770798942 countsByYear W27707989422020 @default.
• W2770798942 countsByYear W27707989422021 @default.
• W2770798942 countsByYear W27707989422022 @default.
• W2770798942 countsByYear W27707989422023 @default.
• W2770798942 crossrefType "journal-article" @default.
• W2770798942 hasAuthorship W2770798942A5000409705 @default.
• W2770798942 hasAuthorship W2770798942A5008158683 @default.
• W2770798942 hasAuthorship W2770798942A5011136856 @default.
• W2770798942 hasAuthorship W2770798942A5011411233 @default.
• W2770798942 hasAuthorship W2770798942A5018001559 @default.
• W2770798942 hasAuthorship W2770798942A5019722619 @default.
• W2770798942 hasAuthorship W2770798942A5026047065 @default.
• W2770798942 hasAuthorship W2770798942A5028677586 @default.
• W2770798942 hasAuthorship W2770798942A5033865459 @default.
• W2770798942 hasAuthorship W2770798942A5038405310 @default.
• W2770798942 hasAuthorship W2770798942A5042137756 @default.
• W2770798942 hasAuthorship W2770798942A5042345692 @default.
• W2770798942 hasAuthorship W2770798942A5042554447 @default.
• W2770798942 hasAuthorship W2770798942A5044874564 @default.
• W2770798942 hasAuthorship W2770798942A5045663008 @default.
• W2770798942 hasAuthorship W2770798942A5046031005 @default.
• W2770798942 hasAuthorship W2770798942A5046159625 @default.
• W2770798942 hasAuthorship W2770798942A5048048621 @default.
• W2770798942 hasAuthorship W2770798942A5049940232 @default.
• W2770798942 hasAuthorship W2770798942A5051505642 @default.
• W2770798942 hasAuthorship W2770798942A5057738047 @default.
• W2770798942 hasAuthorship W2770798942A5078857320 @default.
• W2770798942 hasAuthorship W2770798942A5086730784 @default.
• W2770798942 hasAuthorship W2770798942A5089503365 @default.
• W2770798942 hasAuthorship W2770798942A5090809833 @default.
• W2770798942 hasBestOaLocation W27707989421 @default.
• W2770798942 hasConcept C121608353 @default.
• W2770798942 hasConcept C126322002 @default.
• W2770798942 hasConcept C143998085 @default.
• W2770798942 hasConcept C2777701055 @default.
• W2770798942 hasConcept C2778220009 @default.
• W2770798942 hasConcept C2779984678 @default.
• W2770798942 hasConcept C2781433595 @default.
• W2770798942 hasConcept C31760486 @default.
• W2770798942 hasConcept C535046627 @default.
• W2770798942 hasConcept C71924100 @default.
• W2770798942 hasConceptScore W2770798942C121608353 @default.
• W2770798942 hasConceptScore W2770798942C126322002 @default.
• W2770798942 hasConceptScore W2770798942C143998085 @default.

• next